Analyst Ratings for Krystal Biotech (KRYS)
KRYS Rating Summary
KRYS Price Target Summary
- Highest: $441.00 (Goldman Sachs)
- Lowest: $338.00 (Clear Street)
- Average: $394.33
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$394.33 (+24.6%)
* Over Last 12-Mos
Rating Score: 9.4 / 10
Percentile Rank: 90%
Avg. $ Target:
$394.33 (+24.6%)
* Over Last 12-Mos
Rating Score: 9.4 / 10
Percentile Rank: 90%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/24/2026 | Goldman Sachs | Andrea Newkirk | New Coverage | Buy (N/A) |
441.00 (N/A) |
350.88 (316.58) |
-9.78% | Details |
| 8/14/2026 | RBC Capital | N/A | New Coverage | Outperform (N/A) |
400.00 (N/A) |
328.34 (316.58) |
-3.58% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
